Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Also received tentative approval for 137 mg
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Subscribe To Our Newsletter & Stay Updated
